Lisziewicz Julianna, Kelly Laurene, Lori Franco
Research Institute for Genetic and Human Therapy (RIGHT), Washington, DC, USA.
Curr Drug Deliv. 2006 Jan;3(1):83-8. doi: 10.2174/156720106775197574.
DermaVir employs a topical, non-invasive method for vaccine delivery to dendritic cells. The vaccine product contains plasmid DNA as the active ingredient, encoding authentically expressed retroviral genes with appropriate safety modifications. The non-viral delivery system packages the DNA within pathogen-like nanoparticles and studies indicate that vaccine antigens are taken up by epidermal Langerhans cells, the precursors of dendritic cells. DermaVir loaded dendritic cells reach the draining lymph node target but not the bloodstream nor indiscriminately other organ systems. Safety data from DermaVir immunized infected macaques indicate improved survival, absence of apparent toxicities other than transient erythema and lack of recombination between the vaccine DNA and the infectious viral DNA integrated in the host genome. DermaVir represents a potential new approach for the treatment of HIV infection to be utilized either in conjunction with antiretroviral therapy or during structured treatment interruption.
DermaVir采用一种局部、非侵入性的方法将疫苗递送至树突状细胞。该疫苗产品含有质粒DNA作为活性成分，编码经过适当安全修饰的真实表达的逆转录病毒基因。非病毒递送系统将DNA包裹在病原体样纳米颗粒中，研究表明疫苗抗原被树突状细胞的前体——表皮朗格汉斯细胞摄取。负载DermaVir的树突状细胞到达引流淋巴结靶点，但不会进入血液循环，也不会随意进入其他器官系统。来自接种DermaVir的受感染猕猴的安全性数据表明，其存活率提高，除了短暂红斑外无明显毒性，且疫苗DNA与整合在宿主基因组中的感染性病毒DNA之间无重组现象。DermaVir代表了一种治疗HIV感染的潜在新方法，可与抗逆转录病毒疗法联合使用，或在结构化治疗中断期间使用。
